Involvement of the α4β2 nicotinic receptor subtype in nicotine-induced attenuation of Δ9-THC cerebellar ataxia: Role of cerebellar nitric oxide

Pharmacology Biochemistry and Behavior

Volumn 86, Issue 1, 2007, Pages 103-112

  Smith, Aaron David ^a   Dar, M Saeed ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

9 THC; 4 2 nAChR subtype; Ataxia; Cerebellum; Nicotine; Nitric oxide; RJR 2403

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ALPHA4 BETA2 NICOTINIC RECEPTOR; DRONABINOL; GUANYLATE CYCLASE; ISOLIQUIRITIGENIN; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE; NICOTINIC RECEPTOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; RECEPTOR SUBTYPE; S METHYLPSEUDOTHIOUREA; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; 1H (1,2,4)OXADIAZOLO(4,3 A)QUINOXALIN 1 ONE; 1H-(1,2,4)OXADIAZOLO(4,3-A)QUINOXALIN-1-ONE; CANNABINOID 1 RECEPTOR; CHALCONE DERIVATIVE; CYCLIC GMP; DRUG DERIVATIVE; ENZYME INHIBITOR; METANICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; OXADIAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLAR ATAXIA; CONTROLLED STUDY; DOSE RESPONSE; INFUSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST; SIGNAL TRANSDUCTION; ANIMAL; AREA UNDER THE CURVE; BODY EQUILIBRIUM; CEREBELLUM; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MICROINJECTION; PHYSIOLOGY; STEREOTAXIC SURGERY;

MUS;

ANIMALS; AREA UNDER CURVE; CEREBELLAR ATAXIA; CEREBELLUM; CHALCONES; CYCLIC GMP; ENZYME INHIBITORS; GUANYLATE CYCLASE; MALE; MICE; MICROINJECTIONS; MUSCULOSKELETAL EQUILIBRIUM; NICOTINE; NICOTINIC AGONISTS; NITRIC OXIDE; NITROPRUSSIDE; OXADIAZOLES; QUINOXALINES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, NICOTINIC; STEREOTAXIC TECHNIQUES; TETRAHYDROCANNABINOL;

EID: 33847061320     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.12.013     Document Type: Article

References (49)

1. Adams I.B., and Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (1996) 1585-1614
2. Agosti V., and Levin F.R. Predictors of treatment contact among individuals with cannabis dependence. Am J Drug Alcohol Abuse 30 (2004) 121-127
3. 9-THC-induced central nervous system effects in the mouse. Eur J Neurosci 13 (2001) 561-568
4. 9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 20 (2004) 2737-2748
5. Daiber A., Bachschmid M., Kavakli C., Frein D., Wendt M., Ullrich V., et al. A new pitfall in detecting biological end products of nitric oxide-nitration, nitros(yl)ation and nitrite/nitrate artifacts during freezing. Methods Enzymol 9 (2003) 44-52
6. 1 receptor in the mouse. Brain Res 864 (2000) 186-194
7. Dar M.S., Mustafa S.J., and Wooles W.R. Possible role of adenosine in the CNS effects of ethanol. Life Sci 33 (1983) 1363-1374
8. De Filippi G., Baldwinson T., and Sher E. Evidence for nicotinic acetylcholine receptor activation in rat cerebellar slices. Pharmacol Biochem Behav 70 (2001) 447-455
9. Degenhardt L., Hall W., and Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 364 (2001) 319-327
10. De la Garza R., Bickford-Wimer P.C., Hoffer B.J., and Freedman R. Heterogeneity of nicotine actions in the rat cerebellum: an in vivo electrophysiologic study. J Pharmacol Exp Ther 240 (1987) 689-695
11. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393 (2000) 295-314
12. Ezzati M., and Lopez A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 362 (2000) 847-852
13. Fedele E., and Raiteri M. In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Prog Neurobiol 58 (1999) 89-120
14. Fedele E., Varnier G., Ansaldo M.A., and Raiteri M. Nicotine administration stimulates the in vivo N-methyl-d-aspartate receptor/nitric oxide/cyclic GMP pathway in rat hippocampus through glutamate release. Br J Pharmacol 125 (1998) 1042-1048
15. Fernandez-Cancio E.M., and Fernandez-Vitos J.J. Sources of interference in the use of 2,3-diaminonaphthalene for the fluorimetric determination of nitric oxide synthase activity in biological samples. Clin Chim Acta 312 (2001) 205-212
16. Fonseca F.R., Arco I.D., Martin-Calderon J.L., Gorriti M.A., and Navarro M. Role of endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5 (1998) 483-501
17. Hartell N.A. Receptors, second messengers and protein kinases required for heterosynaptic cerebellar long-term depression. Neuropharmacology 40 (2001) 148-161
18. Hartell N.A., Furuya S., Jacoby S., and Okada D. Intracellular action of nitric oxide increases cGMP in cerebellar Purkinje cells. Neuroreport 12 (2000) 25-28
19. Herkenham M., Groen B.G., Lynn A.B., DeCosta B.R., and Richfield E.K. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res 552 (1991) 301-310
20. Herman B.H., Vocci F., and Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology 13 (1995) 269-293
21. 1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 459 (1999) 277-281
22. Jeon Y.J., Yang K.H., Pulaski J.T., and Kaminski N.E. Attenuation of inducible nitric oxide gene expression by Δ9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation. Mol Pharmacol 50 (1996) 334-341
23. Kamisaki Y., Maeda K., Ishimura M., Omura H., Moriwaki Y., and Itoh T. No enhancement by nitric oxide of glutamate release from P2 and P3 synaptosomes of rat hippocampus. Brain Res 644 (1994) 128-134
24. 9-tetrahydrocannabinol in rats. Behav Pharmacol 17 (2006) 195-199
25. Levenes C., Daniel H., Soubrie P., and Crepel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol 510 (1998) 867-879
26. Lloyd G.K., and Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292 (2000) 461-467
27. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327 (1993) 535-550
28. Misko T.P., Schilling R.J., Salvemini D., Moore W.M., and Currie M.G. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 214 (1993) 11-16
29. Nakayama H., Shioda S., Nakajo S., Ueno S., Nakashima T., and Nakai Y. Immunocytochemical localization of nicotinic acetylcholine receptor in the rat cerebellar cortex. Neurosci Res 29 (1997) 233-239
30. 1 receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 297 (2001) 629-637
31. Picciotto M.R., Caldarone B.J., King S.L., and Zachariou V. Nicotinic receptors in the brain: links between molecular biology and behavior. Neuropsychopharmacology 22 (2000) 451-465
32. Pogun S., Demirgoren S., Taskiran D., Kanit L., Yilmaz O., Koylu E.O., et al. Nicotine modulates nitric oxide in rat brain. Eur Neuropsychopharmacol 10 (2000) 463-472
33. Rao A.M., Dogan A., Hatcher J.F., and Dempsey R.J. Fluorometric assay of nitrite and nitrate in brain tissue after traumatic brain injury and cerebral ischemia. Brain Res 793 (1998) 265-270
34. 3H]-l-glutamate by stimulation of nicotinic acetylcholine receptors in rat cerebellar slices. Neuroscience 124 (2004) 647-653
35. Rodrigo J., Spingall D., Uttenthal O., Bentura M.L., Riveros-Moreno V., Abadía-Molina F., et al. Localization of nitric oxide synthase in the adult rat brain. Philos Trans R Soc B 345 (1994) 175-221
36. Seo D.O., and Rivier D.O. Interaction between alcohol and nitric oxide on ACTH release in the rat. Alcohol Clin Exp Res 27 (2003) 989-996
37. Shim I., Kim H.T., Kim Y.H., Chun B.G., Hahm D.H., Lee E.H., et al. Role of nitric oxide synthase inhibitors and NMDA receptor antagonist in nicotine-induced behavioral sensitization in the rat. Eur J Pharmacol 443 (2002) 119-124
38. Sidman R.L., Angevine Jr. J.B., and Pierce E.T. Atlas of the mouse brain and spinal cord (1971), Harvard University Press, Cambridge
39. Simmons M.S., and Tashkin D.P. The relationship of tobacco and marijuana smoking characteristics. Life Sci 56 (1995) 2185-2191
40. Slotnick B.M., and Leonard C.M. A stereotaxic atlas of albino mouse forebrain (1995), US Government Printing Office, Washington, DC
41. 2 subtype. Brain Res 1115 (2006) 16-25
42. Smith D.A., Hoffmann G.A., David D.J., Adams C.E., and Gerhardt G.A. Nicotine-evoked NO release in the rat hippocampal slice. Neurosci Lett 255 (1998) 127-130
43. Szabo B., Than M., Thorn D., and Wallmichrath I. Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of rats. J Pharmacol Exp Ther 310 (2004) 915-925
44. Takahashi K.A., and Linden D.J. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J Neurophysiol 83 (2000) 1167-1180
45. 4 receptors: sufficient for reward, tolerance, and sensitization. Science 306 (2004) 1029-1032
46. 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135 (2002) 564-578
47. Vincent S.R., Williams J.A., Reiner P.B., and El-Husseini A.D. Monitoring neuronal NO release in vivo in cerebellum, thalamus and hippocampus. Prog Brain Res 118 (1998) 27-35
48. Watson S.J., Benson J.A., and Joy J.E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 57 (2000) 547-552
49. 3H]-labeled adenosine agonist/antagonist following their intrastriatal microinfusion. Methods Find Exp Clin 18 (1996) 373-386